IONIS
Bookmark
ShareCopied to clipboardIONIS is a company. It is a public company in Carlsbad, the United States. It was founded in 1989 and its current CEO is Brett P. Monia. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Carlsbad
- state: CA
- country: United States
- employees: 660 people
- revenues: 848.8M $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 1989
- CEO: Brett P. Monia
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about IONIS:
Dataset of stocks from IONIS:
IONIS is one of the companies in the United States, companies in Biotechnology, companies in Health Care, companies in Carlsbad and 3,456,808 companies in our database.
Talking Points
- Innovating to Change the Course of Human Health | IONIS
- Discover how we are enabling better futures for people living with serious disease through groundbreaking innovations. Learn about our mission here.
- Delivering innovative medicines to patients where no others have proven effective or existed. See our community guidelines: https://t.co/HWH9JQR41u
- YES happens here @Ionispharma | For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and ...
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.